Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Interest Expenses (2021 - 2026)

bioAffinity Technologies has reported Interest Expenses over the past 5 years, most recently at $8938.0 for Q1 2026.

  • Quarterly Interest Expenses fell 42.28% to $8938.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $966946.0 through Mar 2026, up 1743.94% year-over-year, with the annual reading at $502429.0 for FY2025, 4828.67% up from the prior year.
  • Interest Expenses was $8938.0 for Q1 2026 at bioAffinity Technologies, down from $471126.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $896502.0 in Q3 2022 and troughed at $8.0 in Q4 2024.
  • The 5-year median for Interest Expenses is $15091.0 (2024), against an average of $153694.6.
  • Year-over-year, Interest Expenses crashed 99.94% in 2024 and then skyrocketed 5888975.0% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $89290.0 in 2022, then tumbled by 84.3% to $14021.0 in 2023, then crashed by 99.94% to $8.0 in 2024, then skyrocketed by 5888975.0% to $471126.0 in 2025, then plummeted by 98.1% to $8938.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Interest Expenses are $8938.0 (Q1 2026), $471126.0 (Q4 2025), and $3839.0 (Q3 2025).